Madison-based cancer diagnostics startup Elephas Biosciences Corp. has raised $41.5 million in a Series B financing round as it prepares to launch two human clinical trials, the company announced Tuesday.
The startup is building a platform designed to determine whether a given type of therapy will work for a patient before their treatment begins. Its technology tests patient biopsies against different drugs, and uses advanced 3D imaging and artificial intelligence to predict their effectiveness.
Elephas said it’s launching the clinical trials in the next quarter. Next year, it plans to share initial clinical data and make the platform available to biopharma researchers, according to the announcement.